Clinical Trials Logo

Filter by:
NCT ID: NCT06378242 Not yet recruiting - Clinical trials for High-risk Non-muscle Invasive Bladder Cancer

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Start date: April 23, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2

NCT ID: NCT06378177 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Start date: May 17, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of LVGN6051 (4-1BB agonistic antibody) combined with toripalimab (anti-PD-1 antibody) and paclitaxel (anti-tubulin chemotherapy) in patients with recurrent/metastatic head and neck squamous cell carcinoma who rapidly progress from previous neoadjuvant, curative, or adjuvant platinum-containing therapy, or who are currently contraindicated for platinum-containing treatment.

NCT ID: NCT06378138 Not yet recruiting - Clinical trials for Hematologic Malignancies

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: April 25, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT ID: NCT06378060 Recruiting - Clinical trials for Severe Aplastic Anemia

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.

NCT ID: NCT06377956 Not yet recruiting - Food Preferences Clinical Trials

The Associations Between Gut Length, Gut Microbiota and Food Assimilation

Start date: May 15, 2024
Phase:
Study type: Observational

The purpose of this observational study is to explore the relationships between gut length, the microbiota and food energy assimilation rates in humans.

NCT ID: NCT06377761 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Study on Heart Failure With Preserved Ejection Fraction With Qishen Granules

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

With the cardiopulmonary exercise testing as the primary outcome, the study aims to evaluate the efficacy of Qishen Granules on cardiac function, quality of life and biomarker level of patients with heart failure with preserved ejection fraction (HFpEF), which will provide evidence for the treatment of HFpEF with traditional Chinese medicine.

NCT ID: NCT06377735 Recruiting - Clinical trials for Squamous Cell Carcinoma

BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

NCT ID: NCT06377683 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer, mCRPC

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: April 5, 2024
Phase: Phase 1
Study type: Interventional

Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC). Prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein mostly specific to the prostate. While PSMA is expressed at low levels in normal prostate, this expression increased by 100-1000-fold in PC, which makes it a favorable target for therapy. This study was designed to evaluate the safety, tolerability, and maximum tolerated dose of a long-lasting radiolabeled ligand 177Lu-Dansyl-PSMA in mCRPC patients.

NCT ID: NCT06377072 Recruiting - Clinical trials for Cervical Spondylotic Myelopathy

Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy

Start date: May 11, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Shenqi Sherong Pill in participants with Mild or Moderate Cervical Spondylotic Myelopathy (qi deficiency, blood stasis and kidney deficiency type) which based on placebo-control, providing a basis for drug registration.

NCT ID: NCT06376773 Completed - Neoadjuvant Therapy Clinical Trials

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Start date: June 1, 2022
Phase:
Study type: Observational

Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications.